Innovative Blood Collection Device Boosts Participation in Decentralized Clinical Trials with Ben Casavant Tasso TRANSCRIPT
Release Date: 06/05/2024
Driving Interoperability and Ubiquitous Access to Healthcare Information with Dr. John Blair MedAllies TRANSCRIPT
Empowered Patient Podcast
Dr. John Blair, CEO of MedAllies, was created to address the lack of communication and coordination between healthcare providers and the importance of interoperability in healthcare. While healthcare has become more complicated over the years, with advancements in technology and automation, the lack of reimbursement for coordination of care has contributed to the problem of lack of interoperability. There are incentives and penalties associated with interoperability, including information blocking and the Trust Exchange Framework and Common Agreement (TEFCA) initiative, which aims to...
info_outline
Driving Interoperability and Ubiquitous Access to Healthcare Information with Dr. John Blair MedAllies
Empowered Patient Podcast
Dr. John Blair, CEO of MedAllies, was created to address the lack of communication and coordination between healthcare providers and the importance of interoperability in healthcare. While healthcare has become more complicated over the years, with advancements in technology and automation, the lack of reimbursement for coordination of care has contributed to the problem of lack of interoperability. There are incentives and penalties associated with interoperability, including information blocking and the Trust Exchange Framework and Common Agreement (TEFCA) initiative, which aims to...
info_outline
Universal Approach to Cell Therapy Using SNAP-CAR with Dave Mehalick Coeptis Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dave Mehalick, Chairman, Co-Founder, President, and CEO of Coeptis Therapeutics, focuses on developing cell therapies for oncology and respiratory diseases. They aim to create a universal cell therapy that can be used for various types of cancer and move it from a later line of treatment to a frontline therapy. The company has developed a unique CAR therapy called SNAP-CAR, which utilizes off-the-shelf cells and a targeting mechanism to attack cancer cells at different points, making it difficult for the cells to mutate and evade treatment. Coeptis is conducting clinical trials using its...
info_outline
Universal Approach to Cell Therapy Using SNAP-CAR with Dave Mehalick Coeptis Therapeutics
Empowered Patient Podcast
Dave Mehalick, Chairman, Co-Founder, President, and CEO of Coeptis Therapeutics, focuses on developing cell therapies for oncology and respiratory diseases. They aim to create a universal cell therapy that can be used for various types of cancer and move it from a later line of treatment to a frontline therapy. The company has developed a unique CAR therapy called SNAP-CAR, which utilizes off-the-shelf cells and a targeting mechanism to attack cancer cells at different points, making it difficult for the cells to mutate and evade treatment. Coeptis is conducting clinical trials using its...
info_outline
Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC TRANSCRIPT
Empowered Patient Podcast
Ross Bundy, President and CEO of CRISPR QC, shines a light on the current state of CRISPR gene editing technology and how the field has advanced rapidly since the discovery of CRISPR's potential to edit the human genome. The focus of CRISPR technology has primarily been on curing rare and genetic diseases, but there is also potential for targeting cancer tumors' resistance to chemotherapy and the development of customized therapies for various indications. The services offered by CRISPR QC include a unique sensor platform and data analytics capability to monitor and control the gene editing...
info_outline
Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC
Empowered Patient Podcast
Ross Bundy, President and CEO of CRISPR QC, shines a light on the current state of CRISPR gene editing technology and how the field has advanced rapidly since the discovery of CRISPR's potential to edit the human genome. The focus of CRISPR technology has primarily been on curing rare and genetic diseases, but there is also potential for targeting cancer tumors' resistance to chemotherapy and the development of customized therapies for various indications. The services offered by CRISPR QC include a unique sensor platform and data analytics capability to monitor and control the gene editing...
info_outline
Therapeutic Cancer Vaccines with Nicolas Poirier OSE Immunotherapeutics TRANSCRIPT
Empowered Patient Podcast
Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant. The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and OSE aims to re-educate these cells to recognize and eliminate cancer cells or restore immune tolerance in autoimmune diseases. He also discusses the potential of cancer vaccines in re-educating the immune system to target cancer cells, and the importance of combination...
info_outline
Therapeutic Cancer Vaccines with Nicolas Poirier OSE Immunotherapeutics
Empowered Patient Podcast
Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant. The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and OSE aims to re-educate these cells to recognize and eliminate cancer cells or restore immune tolerance in autoimmune diseases. He also discusses the potential of cancer vaccines in re-educating the immune system to target cancer cells, and the importance of combination...
info_outline
Innovative Blood Collection Device Boosts Participation in Decentralized Clinical Trials with Ben Casavant Tasso TRANSCRIPT
Empowered Patient Podcast
Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection...
info_outline
Innovative Blood Collection Device Boosts Participation in Decentralized Clinical Trials with Ben Casavant Tasso
Empowered Patient Podcast
Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection...
info_outlineBen Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection options to accommodate different lab processes and sample types.
Ben explains, "When we think about the customer bases we're serving, we're working with many different pharmaceutical companies conducting critical and life-changing research. We just announced a partnership with the Parkinson's Foundation so they can help find ways to gather information and data about patients living with Parkinson's disease. But they need that access and data from patients. By working with Tasso, we enable them to have that reach and accessibility."
"When we're working with various pharmaceutical companies. They're seeing this real need to get subjects into their trials, to ease recruitment, to help make sure they're hitting their recruitment targets. To help make sure that as a patient goes through a clinical trial, they're able to meet all the data points that are needed so that they can have a completed data set for their own submission. And broadly, in that industry, we're seeing this huge shift. It's really exciting that pharma companies, sponsors, and CROs are looking for more tools to provide patients with better access and lower the barrier, lowering the bar for people to participate in these trials."
#Tassoinc #DecentalizedClinicalTrials #DCT #ClinicalTrials #HealthTechnology #HealthTech
